← Back to Patent Explorer
US5215989A Expired / Lapsed US ⏱️ 0.0 years remaining

Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents

Assignee: Merck and Co Inc
•
Filing: 1991-07-15
•
Granted: 1993-06-01
•
Expires: 2011-07-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of structural formula: <IMAGE> wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members, X and Y are bridging groups, Q is a nitrogen containing heterocycle, R2 and R3 are H, substituted or unsubtituted C1-3 alkyl, C1-3alkoxy, N(R)2, halogen, CF3 or R5 and R1 is H or an aryl group.

Inventors

  • 👤 John J. Baldwin
  • 👤 David A. Claremon
  • 👤 Jason M. Elliott
  • 👤 Gerald S. Ponticello
  • 👤 David C. Remy
  • 👤 Harold G. Selnick

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 15:34
CPC Classifications
C; C07; C07D; C07D335/00; C07D335/04; C07D335/06; C07D211/00; C07D211/04; C07D211/06; C07D211/08; C07D211/18; C07D211/30; C07D211/32; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/36; C07D213/38; C07D401/00; C07D401/02; C07D401/06; C07D409/00; C07D409/02; C07D409/12; C07D495/00; C07D495/02; C07D495/04

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 432 words
Compounds of structural formula: ##STR17## or a pharmaceutically acceptable salt thereof, wherein: Ar is an aromatic ring selected from; 1) benzo, 2) thieno, 3) furo, and 4) pyrrolo; B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from: 1) S--(O) p , wherein p is 0, 1 or 2, 2) C(R) 2 wherein the R groups are the same or different and represent hydrogen or C 1-5 alkyl, 3) C═O, 4) CHOR, 5) --O-- and 6) NR; Q is piperazine or imidazole; X is --CO--, --CO--NR--(CR 2 ) m --, --SO 2 -- or --(CR 2 ) m -- , wherein m is 0, 1, 2 or 3, or a bond when m is O; Y is --(CR 2 )n--, wherein n is 0, 1, 2 or 3; R 1 is hydrogen if Q is imidazolyl, or if Q is other than imidazolyl, R 1 is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thienyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R 2 , R 3 or R 5 , wherein: R 5 is 1) --N(R)SO 2 C 1-6 alkyl; 2) --N(R)SO 2 (CH 2 ) m CO 2 C 1-6 alkyl; 3) --NO 2 ; 4) --N(R)COC 1-6 alkyl; 5) --N(R)SO 2 --C 6 H 4 --R; 6) --N(R)COC 6 H 4 R; 7) --C 2-6 alkanoyl; 8) CON(R) 2 ; 9) --CN; 10) --CO 2 C 1-6 alkyl; 11) benzoyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 12) --NRCOO(C 1-6 alkyl); 13) --NRCOOphenyl either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy or halo; 14) --NRCON(R) 2 ; 15) --S(O) p C 1-6 alkyl, wherein p is 0, 1 or 2; 16) --S(O) p phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy, or halo; 17) phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 18) imidazolyl; or 19) --SO 2 N(R) 2 ; R 2 and R 3 are independently selected from: 1) hydrogen; 2) C 1-3 alkyl either unsubstituted or substituted with a)--N(R) 2 b)--CON(R) 2 c)--CO(C 1-6 alkyl), d)--O(C 1-6 alkyl), e)--OH, or f)--S(O)p(C 1-6 alkyl); 3) C 1-3 alkoxy; 4) --N(R) 2 ; 5) halo or 6) CF 3 ; 7) R 5 . with the proviso that if R 1 is substituted phenyl, with other than an R 5 substitutent, then one of R 2 or R 3 in the ##STR18##
Claim 2
Dependent Claim 432 words
Compounds of structural formula: ##STR17## or a pharmaceutically acceptable salt thereof, wherein: Ar is an aromatic ring selected from; 1) benzo, 2) thieno, 3) furo, and 4) pyrrolo; B is benzo or other carbocyclic or heterocyclic moiety of 5-7 members fused to the aromatic ring, Ar, with up to 3 variable members independently selected from: 1) S--(O) p , wherein p is 0, 1 or 2, 2) C(R) 2 wherein the R groups are the same or different and represent hydrogen or C 1-5 alkyl, 3) C═O, 4) CHOR, 5) --O-- and 6) NR; Q is piperazine or imidazole; X is --CO--, --CO--NR--(CR 2 ) m --, --SO 2 -- or --(CR 2 ) m -- , wherein m is 0, 1, 2 or 3, or a bond when m is O; Y is --(CR 2 )n--, wherein n is 0, 1, 2 or 3; R 1 is hydrogen if Q is imidazolyl, or if Q is other than imidazolyl, R 1 is pyridyl, benzimidazolyl, pyrimidinyl, phenyl, naphthyl, thienyl, thiazolyl, pyrazinyl, quinolinyl, quinoxalinyl, indolyl, or benzofuranyl, either unsubstituted or substituted with one or more of R 2 , R 3 or R 5 , wherein: R 5 is 1) --N(R)SO 2 C 1-6 alkyl; 2) --N(R)SO 2 (CH 2 ) m CO 2 C 1-6 alkyl; 3) --NO 2 ; 4) --N(R)COC 1-6 alkyl; 5) --N(R)SO 2 --C 6 H 4 --R; 6) --N(R)COC 6 H 4 R; 7) --C 2-6 alkanoyl; 8) CON(R) 2 ; 9) --CN; 10) --CO 2 C 1-6 alkyl; 11) benzoyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 12) --NRCOO(C 1-6 alkyl); 13) --NRCOOphenyl either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy or halo; 14) --NRCON(R) 2 ; 15) --S(O) p C 1-6 alkyl, wherein p is 0, 1 or 2; 16) --S(O) p phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, hydroxy, or halo; 17) phenyl, either unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkoxy, halo, or hydroxy; 18) imidazolyl; or 19) --SO 2 N(R) 2 ; R 2 and R 3 are independently selected from: 1) hydrogen; 2) C 1-3 alkyl either unsubstituted or substituted with a)--N(R) 2 b)--CON(R) 2 c)--CO(C 1-6 alkyl), d)--O(C 1-6 alkyl), e)--OH, or f)--S(O)p(C 1-6 alkyl); 3) C 1-3 alkoxy; 4) --N(R) 2 ; 5) halo or 6) CF 3 ; 7) R 5 . with the proviso that if R 1 is substituted phenyl, with other than an R 5 substitutent, then one of R 2 or R 3 in the ##STR18##
Claim 3
Dependent Claim 19 words
A compound of claim 1 wherein B has the structure; ##STR19## wherein W is C═O, CH 2 or CHOH.
Claim 4
Dependent Claim 11 words
A compound of claim 2 wherein B has the structure: ##STR20##
Claim 5
Dependent Claim 34 words
A compound of claim 3 wherein R 1 is pyridyl, benzimidazolyl, pyrimidinyl or phenyl, either unsubstituted or substituted with up to three substituents selected from R 2 , R 3 and R 5 .
Claim 6
Dependent Claim 13 words
A compound of claim 4 wherein R 1 is 2-pyridyl, 6-methyl-2-pyridyl or 4-methanesulfonamidophenyl.
Claim 7
Dependent Claim 26 words
A compound selected from 4-{[4-(2-(2-pyridinyl)ethyl)]-1-piperazinyl}thiochromane; 4-{[2-(4-(nitrophenyl)ethyl)]-1-piperazinyl}thiochromane; N-{[4-(4-thiochromanyl)-1-piperazinyl]ethylphenyl}methanesulfonamide; 2-[4-(2-(4-nitrophenyl)ethyl)-piperazin-1-yl]1-tetralone; 2-[4-(2-(2-pyridylethyl))piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 2-[4-(2-(4-methanesulfonamidophenyl)ethyl)piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-phenylethyl)piperazin-1-yl]1-tetralone; 7-nitro-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-phenylethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 6-methanesulfonamido-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 1-hydroxy-2-[4-(4-nitrophenethyl)piperazin1-yl]tetralin; 1-hydroxy-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]tetralin; 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl]methyl-4H-thieno[2,3-b]-thiopyran-4-one; 1-(indole-5-carbonyl)-4-phenethylpiperazine; 1-(indole-5-carbonyl)-4-[2-(4-methanesulfonamidophenyl)ethyl]piperazine; 1-(1H-indole-5-carbonyl)-4-[2-(4-nitrophenyl)ethyl]piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4oxo-6-carbonyl)-4-(2-(4-nitrophenyl)ethyl)piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(2-(2-pyridyl)ethyl)piperazine, and 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrobenzyl)piperazine.
Claim 8
Dependent Claim 26 words
A compound selected from 4-{[4-(2-(2-pyridinyl)ethyl)]-1-piperazinyl}thiochromane; 4-{[2-(4-(nitrophenyl)ethyl)]-1-piperazinyl}thiochromane; N-{[4-(4-thiochromanyl)-1-piperazinyl]ethylphenyl}methanesulfonamide; 2-[4-(2-(4-nitrophenyl)ethyl)-piperazin-1-yl]1-tetralone; 2-[4-(2-(2-pyridylethyl))piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 2-[4-(2-(4-methanesulfonamidophenyl)ethyl)piperazin-1-yl]-1-tetralone; 7-nitro-2-[4-(2-phenylethyl)piperazin-1-yl]1-tetralone; 7-nitro-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-phenylethyl)piperazin-1-yl]-1-tetralone; 7-methanesulfonamido-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]-1-tetralone; 6-methanesulfonamido-2-[4-(2-(4-nitrophenyl)ethyl)piperazin-1-yl]-1-tetralone; 1-hydroxy-2-[4-(4-nitrophenethyl)piperazin1-yl]tetralin; 1-hydroxy-2-[4-(2-(2-pyridyl)ethyl)piperazin-1-yl]tetralin; 5,6-dihydro-5-[4'-(2-(2-pyridyl)ethyl)piperazin-1'-yl]methyl-4H-thieno[2,3-b]-thiopyran-4-one; 1-(indole-5-carbonyl)-4-phenethylpiperazine; 1-(indole-5-carbonyl)-4-[2-(4-methanesulfonamidophenyl)ethyl]piperazine; 1-(1H-indole-5-carbonyl)-4-[2-(4-nitrophenyl)ethyl]piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4oxo-6-carbonyl)-4-(2-(4-nitrophenyl)ethyl)piperazine; 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(2-(2-pyridyl)ethyl)piperazine, and 1-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-oxo-6-carbonyl)-4-(4-nitrobenzyl)piperazine.
Claim 9
Dependent Claim 17 words
A pharmaceutical formulation comprising a carrier and an effective antiarrhythmic amount of a compound of claim 1.
Claim 10
Dependent Claim 22 words
A pharmaceutical formulation of claim 7 comprising, in addition, a pharmaceutically effective amount of a Class I, II or IV antiarrhythmia agent.
Claim 11
Dependent Claim 31 words
A method for the prevention or treatment of arrhythmia in a member of a mammalian species which comprises the administration of an effective antiarrhythmic amount of a compound of claim 1.
Claim 12
Dependent Claim 24 words
A formulation of claim 7 wherein the amount of the compound is from about 0.0001 to about 20 mg per kg of body weight.
Claim 13
Dependent Claim 24 words
A formulation of claim 7 wherein the amount of the compound is from about 0.001 to about 10 mg per kg of body weight.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-05-31 1996-11-30 1997-06-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-05-31 2000-11-30 2001-06-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-05-31 2004-11-30 2005-06-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag